Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obervation Letter
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Original Article
2018:84:4;419-423
doi: 10.4103/ijdvl.IJDVL_73_16
PMID: 29536977

Intramatricial injections for nail psoriasis: An open-label comparative study of triamcinolone, methotrexate, and cyclosporine

Jyotisterna Mittal, Bharat Bhushan Mahajan
 Department of Dermatology, Venereology and Leprology, Guru Gobind Singh Medical College, Faridkot, Punjab, India

Correspondence Address:
Jyotisterna Mittal
Department of Dermatology, Venereology and Leprology, Shri Guru Ram Das Institute of Medical Sciences and Research, Vallah, Amritsar - 143 001, Punjab
India
Published: 12-Mar-2018
How to cite this article:
Mittal J, Mahajan BB. Intramatricial injections for nail psoriasis: An open-label comparative study of triamcinolone, methotrexate, and cyclosporine. Indian J Dermatol Venereol Leprol 2018;84:419-423
Copyright: (C)2018 Indian Journal of Dermatology, Venereology, and Leprology

Abstract


Background: One of the most effective options available for treating psoriatic fingernails is intramatricial injection of triamcinolone acetonide. Efficacies of intramatricial methotrexate and cyclosporine have not been comparatively evaluated to date.
Methods: Ninety fingernails in 17 patients were assigned to three groups of thirty nails each, and treated with intramatricial injections of triamcinolone acetonide (10 mg/ml), methotrexate (25 mg/ml) and cyclosporine (50 mg/ml) respectively. Each nail was given two injections with a 6-week interval, and graded at 24 weeks using the Nail Psoriasis Severity Index.
Results: In both triamcinolone acetonide and methotrexate groups, 15 (50%) nails out of 30 showed >75% improvement. In the cyclosporine group, only ten (33%) nails showed >75% improvement. Side effects were most in the nails treated with cyclosporine.
Limitations: The limited follow-up period of 24 weeks may have been insufficient for detecting delayed remissions. The number of patients was small and there was no randomization or blinding. The lack of a placebo/ no- treatment arm can be considered a limitation.
Conclusions: Amongst the three drugs studied, intramatricial methotrexate injection yielded the most improvement with minimum side effects, results being comparable to intramatricial triamcinolone acetonide injection. Cyclosporine was the least effective drug, with the most side effects. Intramatricial injection therapy is a safe, economical, simple and effective therapeutic modality in the management of nail psoriasis.
Keywords: Cyclosporine, intralesional injection, intramatricial injection, methotrexate, nail psoriasis, triamcinolone acetonide

Introduction

Psoriasis is one of the most common causes of nail dystrophy. Reported nail involvement in psoriasis varies from 32% to 74% of cases in various Indian studies.[1],[2] Psoriasis of the fingernails constitutes a significant social problem.[3]

Intramatricial corticosteroid injections have been used for many years in nail psoriasis with good results, the steroid of choice being triamcinolone acetonide. Methotrexate as intra-articular injections has been widely used in psoriatic arthritis in doses of 10–20 mg/dose. We found only one report of the use of intralesional methotrexate in a patient with nail psoriasis.[4] Intramatricial cyclosporine has not previously been tried in nail psoriasis, though intralesional cyclosporine (17 mg/ml) yielded significant improvements in chronic plaque psoriasis in double-blind, vehicle-controlled studies, suggesting that cyclosporine is capable of exerting beneficial effects by a local mechanism.[5] Most patients continued to show improvements in the injected cutaneous psoriatic lesions for 4 weeks after intralesional cyclosporine therapy had ended, without significant local or systemic toxic reactions. Taking these factors into account, we took up a trial to comparatively evaluate the therapeutic efficacies of intramatricial injections of triamcinolone acetonide, methotrexate and cyclosporine.

Methods

Our study was carried out at GGS Medical College, Faridkot. The study protocol was approved by the institutional Ethical Committee. Written informed consent was obtained from all participants.

Patients having at least three affected fingernails with or without concomitant skin lesions who had not been on any systemic and topical antipsoriatic medications for at least the past 3 months were enrolled. Children below 10 years, pregnant women, immunocompromised patient, hypertensive and diabetic patients were excluded from the study. In each patient, all the three drugs were injected in different nails, and thus, multiples of three nails were included in the study in each patient. Thus, out of the selected 17 patients, 3, 6 and 9 nails per patient were injected in 5, 11 and 1 patient(s), respectively, making up a total of ninety fingernails injected. Thirty nails each were treated with intramatricial injections of triamcinolone acetonide (10 mg/ml), methotrexate (25 mg/ml) and cyclosporine (50 mg/ml). Hemogram, LFT, RFT, Electolytes were done before 1st and after 2nd injection and at each follow up.

Procedure

With aseptic precautions, the digit was cleaned and draped in a sterilized sheet. Digital nerve blocks with plain lignocaine (2%) were administered in the web spaces on either side of the digit. An insulin syringe was used for the intramatricial injection. The needle was inserted from the lateral angle of the proximal nail fold into the proximal nail matrix, entry into which indicated by a loss of resistance. A volume of 0.05 ml was injected from each lateral angle, forming a 'V' [Figure - 1]. Immediate blanching of the lunula [Figure - 2] indicated that the injection was being given correctly into the proximal nail matrix. Yellowish discoloration of the lunula was seen immediately after an intramatricial injection of methotrexate. This is because of the yellow colour of the injection. Oral serratiopeptidase (20 mg) twice daily was prescribed for 3 days in patients who complained of pain. All patients were advised to clean the treated digits twice daily with povidone-iodine lotion.

Figure 1: Intramatricial injection: positioning of injections
Figure 2: Blanching of the lunula seen immediately after giving an intramatricial injection (left) and yellowish discoloration of the lunula seen immediately after an intramatricial injection of methotrexate (right)

Two injections were administered into each treated nail, with an interval of 6 weeks.

The severity of nail psoriasis was evaluated using the the Nail Psoriasis Severity Index (NAPSI). Herein, each nail is divided into four imaginary quadrants. One point each is assigned for nail matrix signs (pits, leukonychia, red spots in lunulae, crumbling,) and nail bed signs (subungual hyperkeratosis, oil drop sign, splinter hemorrhages, distal onycholysis) in every quadrant. Thus, each nail has a nail matrix score of 0–4 and nail bed score of 0–4, together making up the Nail Psoriasis Severity Index score of 0–8. Changes in Nail Psoriasis Severity Index score were recorded clinically as well as with photographs at 12, 16, 20 and 24 weeks [Table - 1]. Assessment was done by the same investigator at each visit. There was no blinding. Grading of improvement in the Nail Psoriasis Severity Index score was done as follows:

Table 1: Nail-wise comparison of Nail Psoriasis Severity Index scores at weeks 0 and 24 across all three treatment groups
  • G0 = No improvement
  • G1 = 25%–50% improvement
  • G2 = 51%–75% improvement
  • G3 = 76%–99% improvement
  • G4 = Complete recovery.

Data collected were tabulated in a Microsoft Excel worksheet. Results were statistically analyzed using a Chi-square test.

Results

This study was started with 20 patients. 3 were lost to follow up. In the patients who completed the follow ups, 90 fingernails in 17 patients were treated. 9 out of 17 patients were in the age group of 31–50 years(53%). Male-to-female ratio was 3.5:1. The duration of nail psoriasis varied from 1 year to 20 years. The mean duration was 7 years. The number of fingernails affected varied from three in 39% of cases to all ten nails in 6% of the patients. The total Nail Psoriasis Severity Index scores ranged from 7 to 43. The mean overall NAPSI score per nail was 4.4. Mean NAPSI score per nail in the groups triamcinolone, methotrexate and cyclosporine was 4.06, 4.33 and 4.83 respectively. There was no significant difference in the three groups at baseline.

At the first follow-up at 12 weeks, none of the nails in any of the three groups showed G3 or G4 improvement [Table - 2].

Table 2: Numbers of treated nails showing each grade of response (improvements in the Nail Psoriasis Severity Index) with intramatricial triamcinolone acetonide, methotrexate and cyclosporine at week 12 ( first follow-up)

Fifteen (50%) of the 30 nails treated with triamcinolone acetonide (10 mg/ml) showed G3 to G4 improvement by the fourth follow-up at 24 weeks [Figure - 3] and [Figure - 4], [Table - 3]. Eleven nails out of these thirty showed some side effects, most commonly postinjection numbness in fingers (five nails). This was a short-term side effect lasting for a maximum 24 h after injection. Subungual drug deposition was seen in two nails injected with triamcinolone acetonide, due to the deposition of the powder form of the drug in the nail matrix Figure 4] - left]. Pain on intramatricial injection was noted in only two nails, and subungual hematoma Figure 4] - right] and acute paronychia in one nail each in this group.

Figure 3: Nails treated with triamcinolone acetonide: follow-up at weeks 12, 16, 20 and 24 (clockwise from top left)
Figure 4: Adverse effects with intramatricial triamcinolone acetonide: subungual drug deposition and subungual hematoma
Table 3: Numbers of treated nails showing each grade of response (improvements in the Nail Psoriasis Severity Index) in the three treatment groups week 24 (last follow-up)

In the methotrexate group, 17 (56.7%) nails showed G3 and G4 improvement at 24 weeks [Figure - 5]. This was slightly better than with triamcinolone acetonide, but the difference was not statistically significant (P = 0.627). Of the three treatment groups, intramatricial methotrexate was associated with the lowest frequency (7/30) of side effects. Of these, six were instances of transient postinjection numbness, as with injection triamcinolone. Pain on intramatricial injection occurred only in one nail in this group.

Figure 5: Nails treated with intramatricial methotrexate: follow-up at weeks 12, 16, 20 and 24 (clockwise from top left)

In the cyclosporine group, 10 (33.3%) nails showed G3 and G4 improvement at 24 weeks [Table - 3]. Most (11, 36.7%) of the nails in this group showed only G2 improvement at 24 weeks. In addition, intramatricial cyclosporine injection was associated with the most side effects (28 out of 30 treated nails). Severe pain despite ring block anesthesia was reported in 27 nails while receiving cyclosporine injections. Out of these, pain was severe and lasted for a few hours in about 50% of cases and was persistent for a few days in 8 nails. Postinjection numbness of fingers was seen in 13 nails in this group. Side effects such as proximal onycholysis,(1 nail) and splitting (1 nail) and distortion of the nail plate (2 nails) [Figure - 6], though rare, were seen exclusively with this drug.

Figure 6: Adverse effects with intramatricial cyclosporine: splitting of nail plate and nail plate distortion

No statistically significant differences were found between the three groups at any of the follow-up visits. No systemic complication was noted in any of the patients in our study, and none of the patients developed hypopigmentation or atrophy of the treated nail folds.

Discussion

Morphological features in psoriatic nails include nail plate signs as a result of nail matrix involvement, and nail bed signs (above). Other findings such as trachyonychia and paronychia may be seen. The most common finding is pitting in fingernails and subungual hyperkeratosis in toenails.[6]

A wide range of topical and systemic modalities have been used for treating psoriatic nails, but response is often not satisfactory. Hence, nail psoriasis remains a therapeutic challenge. One of the aims in treating nail disorders is to make the drug available to the nail matrix in an effective concentration. Systemic drugs have to be given in high doses which may result in toxicity and they still may not effectively reach the nail matrix. Topical therapies for nail psoriasis have their own drawbacks, including the potential for local atrophy of the skin and bone, the need for prolonged occlusion and repeated applications, and limited efficacy due to low permeability of the nail plate. Delivering the drug directly into the nail matrix by intramatricial injection therefore seems an attractive option. Only two injections were given per nail at 6- weeks interval. This was done to decrease side effects such as injection side atrophy, disappearance of the phalanx under injection and tendon rupture reported with weekly injections of intralesional triamcinolone. No systemic side effects of intralesional injections have been reported in earlier studies.[4]

Intramatricial injection therapy is a safe, economical, simple and effective modality in the management of nail psoriasis. Pain, the most common side effect, was transient with injections of methotrexate and triamcinolone in our study, but with cyclosporine injections, pain was severe and lasted for a few hours in about 50% of nails and for 2-3 days in 8 nails injected with cyclosporine.

In our study, though the differences in the efficacies of intramatricial triamcinolone acetonide, methotrexate and cyclosporine were not statistically significant, methotrexate yielded the best results with the maximum number of nails showing complete recovery (G4 improvement). It was also the drug most accepted by patients, with the lowest frequency of side effects. Saricaoglu et al. also reported successful use of intralesional methotrexate in a single psoriatic fingernail with no recurrence during a 2-year follow-up period, and no adverse effects.[4] In our study, the results with intramatricial methotrexate were comparable to those with intramatricial triamcinolone acetonide. On the other hand, nails treated with intramatricial cyclosporine demonstrated the maximum number of side effects, including severe pain which can decrease patient compliance. Moreover, the higher response grades (G3 and G4) occurred in fewer nails in this group.

There were certain limitations in our study. It was open-labeled, and the number of patients was small. The limited follow-up of 6 months is not adequate to assess the frequency of relapse of nail psoriasis. Selection bias may also have occurred since there was no randomization. Some improvement in each nail could be due to systemic effects of all drugs, since each patient received all the three drugs. The lack of a placebo/ no- treatment arm can also be considered a limitation since psoriasis of nails can improve spontaneously over 6 months.

Conclusions

Keeping in mind its low cost, fewer treatment visits and minimal side effects, intramatricial therapy is a promising option in nail psoriasis. It may also be useful in other nail dystrophies. This is the first study comparing efficacy of intramatricial triamcinolone, methotrexate and cyclosporine in psoriatic fingernails. Larger multicentric, randomized controlled studies with longer follow-up are required to confirm the results of our study.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References
1.
Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol 2010;76:595-601.
[Google Scholar]
2.
Ghosal A, Gangopadhyay DN, Chanda M, Das NK. Study of nail changes in psoriasis. Indian J Dermatol 2004;49:18-21.
[Google Scholar]
3.
de Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: Results of a recent interview with 1,728 patients. Dermatology 1996;193:300-3.
[Google Scholar]
4.
Saricaoglu H, Oz A, Turan H. Nail psoriasis successfully treated with intralesional methotrexate: Case report. Dermatology 2011;222:5-7.
[Google Scholar]
5.
Burns MK, Ellis CN, Eisen D, Duell E, Griffiths CE, Annesley TM, et al. Intralesional cyclosporine for psoriasis. Relationship of dose, tissue levels, and efficacy. Arch Dermatol 1992;128:786-90.
[Google Scholar]
6.
Lavaroni G, Kokelj F, Pauluzzi P, Trevisan G. The nails in psoriatic arthritis. Acta Derm Venereol Suppl (Stockh) 1994;186:113.
[Google Scholar]

Fulltext Views
1009

PDF downloads
269
Show Sections